<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418834</url>
  </required_header>
  <id_info>
    <org_study_id>0653-112</org_study_id>
    <secondary_id>MK0653-112</secondary_id>
    <secondary_id>2006_549</secondary_id>
    <nct_id>NCT00418834</nct_id>
  </id_info>
  <brief_title>Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at
      high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given
      in combination and two higher doses of atorvastatin on lipid lowering.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieved LDL-C &lt;100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C &lt;70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieved LDL-C&lt;100 mg/dL for Patients Without AVD and LDL-C&lt;70 mg/dL for Patients With AVD at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</measure>
    <time_frame>Baseine and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Triglycerides (TG) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Triglycerides (TG) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1053</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe and atorvastatin</intervention_name>
    <description>ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (unspecified)</intervention_name>
    <description>Placebo (unspecified) daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is age 65 or older

          -  Patient is willing to maintain cholesterol lowering diet

          -  Patient has hyperlipidemia with LDL level greater than 70 mg/dl or 100 mg/dl depending
             on their CHD risk category

        Exclusion Criteria:

          -  A condition which, in the opinion of the investigator, would pose a risk to the
             patient or interfere with participation in the study

          -  Patient is unlikely to be compliant in taking study medication

          -  Patient with chronic or unstable medical condition

          -  Patient is taking unstable doses of medication

          -  Patient drinks more than 2 alcoholic drinks per day

          -  Patient has elevations in certain laboratory values (CK, AST, ALT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <results_reference>
    <citation>Zieve F, Wenger NK, Ben-Yehuda O, Constance C, Bird S, Lee R, Hanson ME, Jones-Burton C, Tershakovec AM. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients &gt; or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol. 2010 Mar 1;105(5):656-63. doi: 10.1016/j.amjcard.2009.10.029. Epub 2009 Dec 24.</citation>
    <PMID>20185012</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <results_first_submitted>August 25, 2009</results_first_submitted>
  <results_first_submitted_qc>August 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2009</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III
First Patient In: 28-Feb-2007; Last Patient Last Visit: 01-Oct-2008
143 centers worldwide (United States, Canada, Poland, Romania, Ukraine and Russia)</recruitment_details>
      <pre_assignment_details>Patients were stratified based on baseline LDL-C levels and presence or absence of atherosclerotic vascular
disease to achieve balance across treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorva 10 mg + EZ</title>
          <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Atorva 20 mg / Atorva 40 mg</title>
          <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="526"/>
                <participants group_id="P2" count="527"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorva 10 mg + EZ</title>
          <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Atorva 20 mg / Atorva 40 mg</title>
          <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="526"/>
            <count group_id="B2" value="527"/>
            <count group_id="B3" value="1053"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.2" lower_limit="65" upper_limit="86"/>
                    <measurement group_id="B2" value="71.2" lower_limit="65" upper_limit="92"/>
                    <measurement group_id="B3" value="71.2" lower_limit="65" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="563"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="503"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="1008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="337"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI [Body Mass Index (&lt;30, ≥30 kg/m2)]</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;30 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apo lipoprotein A-I (Apo A-I)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.3" spread="28.7"/>
                    <measurement group_id="B2" value="164.4" spread="26.8"/>
                    <measurement group_id="B3" value="164.4" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apo lipoprotein B (Apo B)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.6" spread="22.8"/>
                    <measurement group_id="B2" value="101.8" spread="21.4"/>
                    <measurement group_id="B3" value="102.7" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apo lipoprotein B (Apo B):Apo lipoprotein A-I (Apo A-I) Ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6" spread="0.2"/>
                    <measurement group_id="B2" value="0.6" spread="0.2"/>
                    <measurement group_id="B3" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein Cholesterol (HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="13.6"/>
                    <measurement group_id="B2" value="54.5" spread="12.3"/>
                    <measurement group_id="B3" value="54.7" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highly selective C-reactive protein (hs-CRP)</title>
          <description>Robust Standard Deviation was calculated for hs-CRP as: interquartile range
(IQR)/1.075, where IQR=3rd quartile - 1st quartile.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="2.7"/>
                    <measurement group_id="B2" value="1.9" spread="2.3"/>
                    <measurement group_id="B3" value="1.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein Cholesterol (LDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.9" spread="27.7"/>
                    <measurement group_id="B2" value="101.8" spread="20.7"/>
                    <measurement group_id="B3" value="102.3" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="0.7"/>
                    <measurement group_id="B2" value="2.0" spread="0.6"/>
                    <measurement group_id="B3" value="2.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High Density Lipoprotein Cholesterol (Non-HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128.2" spread="30.6"/>
                    <measurement group_id="B2" value="127.2" spread="25.2"/>
                    <measurement group_id="B3" value="127.7" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High Density Lipoprotein Cholesterol (Non-HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ra</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="0.9"/>
                    <measurement group_id="B2" value="2.5" spread="0.8"/>
                    <measurement group_id="B3" value="2.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183.1" spread="31.8"/>
                    <measurement group_id="B2" value="181.8" spread="26.1"/>
                    <measurement group_id="B3" value="182.4" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol (TC):High Density Lipoprotein-C (HDL-C) Ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="0.9"/>
                    <measurement group_id="B2" value="3.5" spread="0.8"/>
                    <measurement group_id="B3" value="3.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (TG)</title>
          <description>Robust Standard Deviation was calculated for Triglycerides as: interquartile range (IQR)/1.075, where IQR=3rd quartile - 1st quartile.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112.8" spread="55.3"/>
                    <measurement group_id="B2" value="116.5" spread="60.0"/>
                    <measurement group_id="B3" value="114.0" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population
includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at
least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication
were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population
includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at
least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication
were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" lower_limit="-28.6" upper_limit="-24.7"/>
                    <measurement group_id="O2" value="-12.8" lower_limit="-14.8" upper_limit="-10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline LDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-16.0</ci_lower_limit>
            <ci_upper_limit>-11.7</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS
population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)
value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind
study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS
population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)
value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind
study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" lower_limit="-25.0" upper_limit="-19.9"/>
                    <measurement group_id="O2" value="-17.9" lower_limit="-20.5" upper_limit="-15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline LDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 6</title>
        <time_frame>Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population
includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at
least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication
were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population
includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at
least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication
were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model terms: treatment, baseline LDL-C, and AVD status</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.52</ci_lower_limit>
            <ci_upper_limit>8.84</ci_upper_limit>
            <estimate_desc>Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS
population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)
value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind
study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS
population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)
value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind
study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model terms: treatment, baseline LDL-C, and AVD status</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
            <estimate_desc>Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg / Atorva 40 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieved LDL-C &lt;100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C &lt;70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6</title>
        <time_frame>Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved LDL-C &lt;100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C &lt;70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;100 mg/dL (w/o AVD) and &lt;70 mg/dL (w/ AVD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;100 mg/dL (w/o AVD) and ≥70 mg/dL (w/AVD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model terms: treatment, baseline LDL-C, and AVD status</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.98</ci_lower_limit>
            <ci_upper_limit>7.55</ci_upper_limit>
            <estimate_desc>Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieved LDL-C&lt;100 mg/dL for Patients Without AVD and LDL-C&lt;70 mg/dL for Patients With AVD at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved LDL-C&lt;100 mg/dL for Patients Without AVD and LDL-C&lt;70 mg/dL for Patients With AVD at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;100 mg/dL (w/o AVD) and &lt;70 mg/dL (w/ AVD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥100 mg/dL (w/o AVD) and ≥70 mg/dL (w/ AVD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model terms: treatment, baseline LDL-C, and AVD status</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
            <estimate_desc>Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg / Atorva 40 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.1" upper_limit="4.0"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-0.8" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.9" upper_limit="3.8"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-2.2" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" lower_limit="-25.2" upper_limit="-21.7"/>
                    <measurement group_id="O2" value="-11.2" lower_limit="-13.0" upper_limit="-9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline non-HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>-10.3</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</title>
        <time_frame>Baseine and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" lower_limit="-22.3" upper_limit="-17.7"/>
                    <measurement group_id="O2" value="-15.8" lower_limit="-18.1" upper_limit="-13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline non-HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC) at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)
value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL)
value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" lower_limit="-17.2" upper_limit="-14.6"/>
                    <measurement group_id="O2" value="-8.0" lower_limit="-9.3" upper_limit="-6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Total Cholesterol, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>-6.5</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" lower_limit="-15.2" upper_limit="-12.0"/>
                    <measurement group_id="O2" value="-11.6" lower_limit="-13.2" upper_limit="-10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Total Cholesterol, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Triglycerides (TG) at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides (TG) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" lower_limit="-14.3" upper_limit="-9.7"/>
                    <measurement group_id="O2" value="-5.7" lower_limit="-8.4" upper_limit="-3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Nonparametric ANCOVA</method>
            <method_desc>ANCOVA using ranks based on normal scores (Tukey method) with model terms for treatment, baseline TG value (normalized scores), and AVD status</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)
The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Triglycerides (TG) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides (TG) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" lower_limit="-13.7" upper_limit="-9.3"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-11.3" upper_limit="-7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Nonparametric ANCOVA</method>
            <method_desc>ANCOVA using ranks based on normal scores (Tukey method) with model terms for treatment, baseline TG value (normalized scores), and AVD status</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)
The median difference is based on the Hodges-Lehmann estimates
of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.8" lower_limit="-18.5" upper_limit="-15.1"/>
                    <measurement group_id="O2" value="-7.7" lower_limit="-9.4" upper_limit="-6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Apo B, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>-7.3</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" lower_limit="-16.1" upper_limit="-11.9"/>
                    <measurement group_id="O2" value="-10.8" lower_limit="-12.9" upper_limit="-8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Apo B, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-2.4" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-3.0" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Apo A-I, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-0.7" upper_limit="2.1"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-3.4" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Apo A-I, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" lower_limit="-18.4" upper_limit="-15.3"/>
                    <measurement group_id="O2" value="-7.9" lower_limit="-9.4" upper_limit="-6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Total-C:HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>-7.3</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" lower_limit="-16.4" upper_limit="-12.5"/>
                    <measurement group_id="O2" value="-9.8" lower_limit="-11.8" upper_limit="-7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Total-C:HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" lower_limit="-29.5" upper_limit="-25.0"/>
                    <measurement group_id="O2" value="-12.6" lower_limit="-14.9" upper_limit="-10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline LDL-C:HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.0</ci_lower_limit>
            <ci_upper_limit>-12.2</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.9" lower_limit="-25.9" upper_limit="-20.0"/>
                    <measurement group_id="O2" value="-16.0" lower_limit="-18.9" upper_limit="-13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline LDL-C:HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>-3.7</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" lower_limit="-16.6" upper_limit="-12.9"/>
                    <measurement group_id="O2" value="-5.2" lower_limit="-7.1" upper_limit="-3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Apo B:Apo A-I, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>-7.5</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" lower_limit="-15.7" upper_limit="-11.3"/>
                    <measurement group_id="O2" value="-8.2" lower_limit="-10.4" upper_limit="-6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline Apo B:Apo A-I, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>-2.9</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" lower_limit="-26.2" upper_limit="-21.8"/>
                    <measurement group_id="O2" value="-11.1" lower_limit="-13.3" upper_limit="-8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline non-HDL-C:HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.3</ci_lower_limit>
            <ci_upper_limit>-10.5</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" lower_limit="-23.2" upper_limit="-17.6"/>
                    <measurement group_id="O2" value="-13.8" lower_limit="-16.6" upper_limit="-10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, baseline non-HDL-C:HDL-C, and AVD status</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>-3.6</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="497"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" lower_limit="-19.6" upper_limit="-6.8"/>
                    <measurement group_id="O2" value="-10.7" lower_limit="-17.0" upper_limit="-3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.534</p_value>
            <method>Longitudinal Data Analysis (LDA)</method>
            <method_desc>LDA method of Liang and Zeger with model terms: treatment, time, AVD status, and the interaction of time by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.9</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg)
Data for analysis was transformed by the natural log and the difference in geometric mean % change from BL calculated based on the difference in the back-transformed least squares means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorva 10 mg + EZ</title>
            <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorva 20 mg / Atorva 40 mg</title>
            <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12</title>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" lower_limit="-27.3" upper_limit="-15.6"/>
                    <measurement group_id="O2" value="-14.6" lower_limit="-20.7" upper_limit="-8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>Longitudinal Data Analysis (LDA)</method>
            <method_desc>LDA method of Liang and Zeger with model terms: treatment, time, AVD status, and the interaction of time by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.6</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Data for analysis was transformed by the natural log and the difference in geometric mean % change from BL calculated based on the difference in the back-transformed least squares means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The number of subjects at risk for reported adverse events is based on an All-Patients-as-Treated population, which includes all randomized patients who received at least one dose of double-blind study therapy</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorva 10 mg + EZ</title>
          <description>[Atorva 10 mg + Ezetimibe 10 mg] orally once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Atorva 20 mg / Atorva 40 mg</title>
          <description>Atorva 20 mg orally once daily for 6 weeks, and up-titrated to Atorva 40 mg orally once daily for an additional 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15"/>
                <counts group_id="E2" subjects_affected="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46"/>
                <counts group_id="E2" subjects_affected="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Asparate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

